Dendreon Corporation (NASDAQ: DNDN)

Dendreon Corporation (NASDAQ: DNDN), a biotechnology company, is focused on targeting cancer and transforming lives through the discovery, development and commercialization of therapeutics. The Company leverages its staff’s expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates that stimulate an immune response. Additionally, Dendreon is developing an orally-available small molecule that targets Trp-p8, which could applicable to multiple types of cancer as well as benign prostatic hyperplasia. For further information, visit the Company’s web site at www.dendreon.com.